These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 29518013)

  • 1. Immunogenicity and Safety of the New Inactivated Quadrivalent Influenza Vaccine Vaxigrip Tetra: Preliminary Results in Children ≥6 Months and Older Adults.
    Montomoli E; Torelli A; Manini I; Gianchecchi E
    Vaccines (Basel); 2018 Mar; 6(1):. PubMed ID: 29518013
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity, reactogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine: a phase III, randomized trial in adults aged ≥18 years.
    Kieninger D; Sheldon E; Lin WY; Yu CJ; Bayas JM; Gabor JJ; Esen M; Fernandez Roure JL; Narejos Perez S; Alvarez Sanchez C; Feng Y; Claeys C; Peeters M; Innis BL; Jain V
    BMC Infect Dis; 2013 Jul; 13():343. PubMed ID: 23883186
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Phase III randomised trial of the immunogenicity and safety of quadrivalent versus trivalent inactivated subunit influenza vaccine in adult and elderly subjects, assessing both anti-haemagglutinin and virus neutralisation antibody responses.
    van de Witte S; Nauta J; Montomoli E; Weckx J
    Vaccine; 2018 Sep; 36(40):6030-6038. PubMed ID: 29709447
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine: a randomized, double-blind, controlled phase III clinical trial in children aged 6-35 months in China.
    Hu Y; Shao M; Hu Y; Liang Q; Jia N; Chu K; Xu L; Li J; Li C; Zhu F
    Hum Vaccin Immunother; 2020 Jul; 16(7):1691-1698. PubMed ID: 32347785
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and immunogenicity of a quadrivalent inactivated influenza vaccine in adults.
    Pépin S; Donazzolo Y; Jambrecina A; Salamand C; Saville M
    Vaccine; 2013 Nov; 31(47):5572-8. PubMed ID: 24016810
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity, reactogenicity, and safety of inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine in healthy adults aged ≥18 years: a phase III, randomized trial.
    Tinoco JC; Pavia-Ruz N; Cruz-Valdez A; Aranza Doniz C; Chandrasekaran V; Dewé W; Liu A; Innis BL; Jain VK
    Vaccine; 2014 Mar; 32(13):1480-7. PubMed ID: 24486352
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Active-controlled phase III study of an egg-cultivated quadrivalent inactivated split-virion influenza vaccine (GC3110A) in healthy Korean children aged 6-35 months.
    Choi UY; Kim KH; Lee KY; Kim JH; Kim CS; Eun BW; Kim HM; Kim DH; Song SE; Jo DS; Lee J; Ma SH; Kim KN; Kang JH
    Vaccine; 2021 Apr; 39(15):2103-2109. PubMed ID: 33736920
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity and safety of an egg-based inactivated quadrivalent influenza vaccine (GC3110A) versus two inactivated trivalent influenza vaccines with alternate B strains: A phase Ⅲ randomized clinical trial in adults.
    Song JY; Lee J; Woo HJ; Wie SH; Lee JS; Kim SW; Kim TH; Jung SI; Noh JY; Choi WS; Cheong HJ; Kim WJ
    Hum Vaccin Immunother; 2019; 15(3):710-716. PubMed ID: 30396317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity and safety of quadrivalent versus trivalent inactivated influenza vaccine: a randomized, controlled trial in adults.
    Beran J; Peeters M; Dewé W; Raupachová J; Hobzová L; Devaster JM
    BMC Infect Dis; 2013 May; 13():224. PubMed ID: 23688546
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A trivalent, inactivated influenza vaccine (Vaxigrip®): summary of almost 50 years of experience and more than 1.8 billion doses distributed in over 120 countries.
    Haugh M; Gresset-Bourgeois V; Macabeo B; Woods A; Samson SI
    Expert Rev Vaccines; 2017 Jun; 16(6):545-564. PubMed ID: 28460594
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quadrivalent inactivated influenza vaccine (VaxigripTetra™).
    Gresset-Bourgeois V; Leventhal PS; Pepin S; Hollingsworth R; Kazek-Duret MP; De Bruijn I; Samson SI
    Expert Rev Vaccines; 2018 Jan; 17(1):1-11. PubMed ID: 29157068
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety, immunogenicity, and lot-to-lot consistency of a split-virion quadrivalent influenza vaccine in younger and older adults: A phase III randomized, double-blind clinical trial.
    Sesay S; Brzostek J; Meyer I; Donazzolo Y; Leroux-Roels G; Rouzier R; Astruc B; Szymanski H; Toursarkissian N; Vandermeulen C; Kowalska E; Van Damme P; Salamand C; Pepin S
    Hum Vaccin Immunother; 2018 Mar; 14(3):596-608. PubMed ID: 28968138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity and safety of inactivated quadrivalent and trivalent influenza vaccines in children 18-47 months of age.
    Rodriguez Weber MA; Claeys C; Aranza Doniz C; Feng Y; Innis BL; Jain VK; Peeters M
    Pediatr Infect Dis J; 2014 Dec; 33(12):1262-9. PubMed ID: 25386965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccines in participants >/=3 years of age: a double-blind, randomized, parallel-controlled phase III clinical trial in China.
    Wang SY; Liu SZ; Chu K; Zhao Y; Zhu FC; Hu YM; Meng FY; Li JX; Luo L; Yang JY; Liu P; Yu J
    Expert Rev Vaccines; 2017 Nov; 16(11):1155-1169. PubMed ID: 28870140
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inactivated quadrivalent split-virus seasonal influenza vaccine (Fluarix® quadrivalent): a review of its use in the prevention of disease caused by influenza A and B.
    McKeage K
    Drugs; 2013 Sep; 73(14):1587-94. PubMed ID: 24022123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and immunogenicity of a quadrivalent inactivated influenza vaccine compared to licensed trivalent inactivated influenza vaccines in adults.
    Greenberg DP; Robertson CA; Noss MJ; Blatter MM; Biedenbender R; Decker MD
    Vaccine; 2013 Jan; 31(5):770-6. PubMed ID: 23228813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and immunogenicity of an inactivated quadrivalent influenza vaccine in children 6 months through 8 years of age.
    Greenberg DP; Robertson CA; Landolfi VA; Bhaumik A; Senders SD; Decker MD
    Pediatr Infect Dis J; 2014 Jun; 33(6):630-6. PubMed ID: 24445833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity and safety of Southern Hemisphere inactivated quadrivalent influenza vaccine: a Phase III, open-label study of adults in Brazil.
    Zerbini CA; Ribeiro Dos Santos R; Jose Nunes M; Soni J; Li P; Jain VK; Ofori-Anyinam O
    Braz J Infect Dis; 2017; 21(1):63-70. PubMed ID: 27912069
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the reactogenicity and immunogenicity of a split and a subunit-adjuvanted influenza vaccine in elderly subjects.
    Squarcione S; Sgricia S; Biasio LR; Perinetti E
    Vaccine; 2003 Mar; 21(11-12):1268-74. PubMed ID: 12559808
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity and safety of quadrivalent versus trivalent inactivated subunit influenza vaccine in children and adolescents: A phase III randomized study.
    Vesikari T; Nauta J; Lapini G; Montomoli E; van de Witte S
    Int J Infect Dis; 2020 Mar; 92():29-37. PubMed ID: 31838217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.